Tabitha Cousart
Nurse Practitioner · Yadkinville, NCNPI 1982839197
Payments from drug & device makers
Across 185 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$607
- AbbVie$468
- Novo Nordisk$330
- GSK$181
- Lilly USA, LLC$141
- Otsuka America Pharmaceutical, Inc.$134
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$592%
- Food & beverage$3,25098%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $607 |
| AbbVie | 39 | $468 |
| Novo Nordisk | 22 | $330 |
| GSK | 10 | $181 |
| Lilly USA, LLC | 8 | $141 |
| Otsuka America Pharmaceutical, Inc. | 8 | $134 |
| Pfizer | 6 | $124 |
| Amgen | 6 | $116 |
| Dexcom, Inc. | 4 | $113 |
| Bayer | 6 | $113 |
| Boehringer Ingelheim | 5 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $84 |
| Sanofi-aventis U.S. LLC | 4 | $77 |
| Mylan Specialty L.p. | 4 | $73 |
| Johnson & Johnson | 4 | $66 |
| Sunovion Pharmaceuticals Inc. | 4 | $64 |
| BD | 2 | $59 |
| Novartis | 4 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Abbott | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Organogenesis Inc. | 1 | $31 |
| Exact Sciences | 2 | $31 |
| Merck | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Organon | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$216
How this compares
$3,309 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $110,319 |
| FarxigaDapagliflozin Propanediol | 119 | $89,639 |
| OzempicSemaglutide | 51 | $86,754 |
| LinzessLinaclotide | 58 | $57,070 |
| MounjaroTirzepatide | 41 | $56,233 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $49,266 |
| RybelsusSemaglutide | 29 | $45,079 |
| JardianceEmpagliflozin | 39 | $44,037 |
| TrulicityDulaglutide | 36 | $43,308 |
| ProliaDenosumab | 23 | $39,760 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $35,275 |
| VascepaIcosapent Ethyl | 58 | $33,461 |
| XareltoRivaroxaban | 21 | $30,788 |
| GemtesaVibegron | 39 | $30,269 |
| VraylarCariprazine Hcl | 19 | $27,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $607 | $146,549209 claims |
| Novo NordiskOzempic, Rybelsus | $330 | $131,83380 claims |
| PfizerEliquis | $124 | $110,31989 claims |
| Lilly USA, LLCMounjaro, Trulicity | $141 | $99,54077 claims |
| AbbVieLinzess, Vraylar | $468 | $84,69677 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $92 | $53,58251 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $181 | $51,68378 claims |
| AmgenProlia | $116 | $39,76023 claims |
| Johnson & JohnsonXarelto | $66 | $30,78821 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $30,26939 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $26,03020 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $134 | $24,29513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.
Other nurse practitioner in Yadkinville
- Sandrivette JohnsonRaleigh$573K
- Skyler RogersPinehurst$174K
- Jamie DinerDurham$170K
- Ayeshia WrightMocksville$145K
- Deborah AllenDurham$112K
- Jeanann VawterGastonia$97K
- Terra KampJacksonville$72K
- Mary DilorenzoCharlotte$71K
- Olivia OgburnWinston Salem$70K
- Bridget ArchambaultDurham$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.